Company / Cash & Equivalents
KalVista Pharmaceuticals, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$131.6M
FY2025
5-year range
$30.7M / $131.6M
FY2021-FY2025
Trend
+314.0%
vs FY2024
Sector context
#121 of 207
Health Care
What the data says
Cash & Equivalents changed +314% YoY in FY2025, a notable deviation from the 9-year average annual change of +135%.
Based on SEC 10-K filings.
$132M in FY2025 with a 5-year CAGR of +52.8%.
Improved from $56M to $132M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +62.4%
- 5-Year CAGR
- +52.8%
- 10-Year CAGR
- -
Sector benchmark
#121 of 207 in Health CareTop 58% of 207This company $131.6M Sector average $669.5M
▼
-80.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +52.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 314.0% year-over-year.
- Ranks #121 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $131.6M | +314.0% |
| FY2024 | $31.8M | -43.5% |
| FY2023 | $56.2M | +83.0% |
| FY2022 | $30.7M | -39.3% |
| FY2021 | $50.6M | +220.4% |
| FY2020 | $15.8M | -27.5% |
| FY2019 | $21.8M | +761.6% |
| FY2018 | $2.5M | -91.8% |
| FY2017 | $30.9M | +42.2% |
| FY2016 | $21.8M | +761.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026